Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment.
Changes in body fat mass were studied in 25 untreated patients with Laron syndrome from childhood into adulthood. It was found that these patients, characterized by marked dwarfism, high plasma hGH and low serum insulin-like growth factor I (IGF-I), develop progressive and marked obesity and have a tendency for elevated serum cholesterol levels. Long-term treatment of 8 children and 5 adults with this syndrome with IGF-I (50-150 micrograms/kg/day s.c.) resulted in a significant decrease in subcutaneous fat in all patients and a lowering of the serum cholesterol and triglycerides, mainly in the adults. As in Laron syndrome the GH receptors are inactive, it is hypothesized that IGF-I exerts a direct effect on adipose tissue metabolism.
Laron
Z
Z
Endocrinology and Diabetes Research Unit, Children's Medical Center of Israel, Petah Tikva.
Klinger
B
B
D000273:Adipose Tissue / Q000000981:diagnostic imaging / Q000473:pathology*; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D004392:Dwarfism / Q000473:pathology*; D004700:Endocrine System Diseases / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D005260:Female; D013006:Growth Hormone / Q000502:physiology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000172:deficiency / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D009765:Obesity / Q000473:pathology*; D012885:Skinfold Thickness; D013577:Syndrome; D014057:Tomography, X-Ray Computed
D008074:Lipoproteins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D002784:Cholesterol